NeuroDex is developing a blood-based biomarker research platform designed to study molecular signals associated with neurological diseases, including Alzheimer’s and Parkinson’s, through neuron-derived extracellular vesicles.

United States, May 21, 2026 -- MASSACHUSETTS, UNITED STATES — May 21, 2026 — NeuroDex, a biotechnology research company, is advancing a blood-based biomarker research platform focused on studying molecular signals linked to neurological diseases. The company’s work centers on neuron-derived extracellular vesicles, microscopic particles released by brain cells that may carry biological information into the bloodstream.

Neurological conditions such as Alzheimer’s disease, Parkinson’s disease, and related disorders often develop gradually before symptoms become clear. This has increased scientific interest in technologies that can help researchers better understand brain biology through less invasive methods.

NeuroDex’s approach focuses on extracellular vesicles, which are naturally released by cells and carry proteins, genetic material, and other molecular information. Neuron-derived vesicles can cross the blood-brain barrier and circulate in blood, creating a potential research pathway for studying brain disease biomarkers.

“Neurons continuously release vesicles that contain important biological information,” said Dr. Erez Eitan, CEO and co-founder of NeuroDex. “By studying these signals, researchers may gain a clearer view of biological changes associated with brain health.”

Focus on Neuron-Derived Vesicle Analysis

The company’s ExoSORT™ technology is designed to isolate neuron-derived extracellular vesicles from blood samples. This step is important because blood contains vesicles from many cell types, while neuron-derived vesicles represent only a small portion of the total.

Once isolated, these vesicles can be analyzed for proteins and other biomarkers associated with neurological disease research. The platform may support studies related to Alzheimer’s early detection, Parkinson’s diagnosis blood test technologies, and broader neurological disease diagnosis research.

NeuroDex emphasized that the platform remains part of ongoing research efforts and is not intended to replace clinical diagnostic procedures.

Supporting Brain Disease Biomarker Research

Interest in blood test for brain disease research has grown as scientists look for ways to better study neurodegenerative conditions. Reliable biomarkers may help researchers monitor disease progression, evaluate treatment response, and improve clinical trial design.

“If researchers want to understand brain biology from blood, specificity is essential,” Dr. Eitan said. “The goal is to ensure that the biological material being analyzed reflects neuronal origin.”

About NeuroDex
NeuroDex is a biotechnology research company focused on blood-based biomarker analysis and neurological disease research involving neuron-derived extracellular vesicles. Its work supports scientific studies related to brain disease biomarkers and molecular signals associated with neurological health.

For more information, visit: https://neurodex.co

About the company: NeuroDex is a Massachusetts-based biotechnology research company developing blood-based biomarker analysis technologies for neurological disease research. The company focuses on neuron-derived extracellular vesicles to study molecular signals associated with brain health and neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. Through its ExoSORT™ technology, NeuroDex aims to support research into brain disease biomarkers, disease progression, treatment response, and clinical trial development.

Contact Info:
Name: Dr. Erez Eitan
Email: Send Email
Organization: NeuroDex
Website: https://neurodex.co

Release ID: 89192645

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.